|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities | |||||
| Depreciation and amortization | |||||
| Net amortization (accretion) of premiums (discounts) on marketable securities | |||||
| Stock-based compensation | |||||
| Amortization of right of use assets | |||||
| Changes in assets and liabilities | |||||
| Accounts receivable | |||||
| Prepaid expenses and other assets | |||||
| Accounts payable | |||||
| Accrued and other liabilities | |||||
| Contract assets and liabilities | |||||
| Contract liabilities | |||||
| Lease liabilities | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities | |||||
| Purchases of property and equipment, net | |||||
| Purchases of marketable securities | |||||
| Maturities of marketable securities | |||||
| Sales of marketable securities | |||||
| Net cash provided by (used in) investing activities | |||||
| Cash flows from financing activities | |||||
| Proceeds from issuance of common stock in public offering, net of issuance costs | |||||
| Proceeds from issuances of pre-funded warrants | |||||
| Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs | |||||
| Proceeds from exercise of common stock options | |||||
| Proceeds from ESPP purchases | |||||
| Net cash provided by financing activities | |||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents and restricted cash, at beginning of period | |||||
| Cash, cash equivalents and restricted cash, at end of period | |||||
| Supplemental disclosure of cash flow information: | |||||
| Cash paid for income taxes | |||||
| Cash paid for interest | |||||
| Supplemental non-cash investing and financing activities: | |||||
| Vesting of early exercised options and restricted stock | |||||
| Right-of-use asset obtained in exchange for a new operating lease liability | |||||
| Purchases of property and equipment in accounts payable and accrued liabilities | |||||
| Unpaid offering costs | |||||
| Unpaid at-the-market offering program costs | |||||
| Reconciliation of cash, cash equivalents and restricted cash | |||||
| Cash and cash equivalents | |||||
| Restricted cash | |||||
Loading...